WO2000051629A1 - Preparations stabilisees a longue conservation - Google Patents
Preparations stabilisees a longue conservation Download PDFInfo
- Publication number
- WO2000051629A1 WO2000051629A1 PCT/JP2000/001160 JP0001160W WO0051629A1 WO 2000051629 A1 WO2000051629 A1 WO 2000051629A1 JP 0001160 W JP0001160 W JP 0001160W WO 0051629 A1 WO0051629 A1 WO 0051629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- methionine
- amino acids
- month
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates to a G-CSF (granulocyte colony stimulating factor) preparation, and in particular, to stabilize a G-CSF methionine residue having a low oxidized product generation rate with a small loss of an active ingredient even after long-term storage.
- G—CSF formulation granulocyte colony stimulating factor
- G—CSF is a glycoprotein with a molecular weight of about 20,000 that acts on neutrophil progenitor cells and promotes their proliferation and differentiation and maturation.
- the applicant Since the applicant has purified high-purity human G-CSF by culturing a cell line collected from tumor cells of a patient with oral floor cancer, this has led to the cloning of the human G-CSF gene. Successful and now it is possible to produce large amounts of recombinant human G-CSF in microorganisms and animal cells by genetic engineering methods. In addition, the applicant of the present invention has succeeded in formulating the purified G-CSF and supplies the purified G-CSF to the market as an anti-infective agent (Patent No. 21 16515).
- G-CSF is used in extremely small amounts, and usually, a dose of 0.1-1000 Ug (preferably 5-500 g) of G-CSF per adult is administered 1-7 times / week I do.
- this G—C S F exhibits adsorptivity to the walls of, for example, ampoules for injection and injectors.
- G-CSF is unstable and susceptible to external factors, causing physical and chemical changes such as association, polymerization or oxidation due to temperature, humidity, oxygen, ultraviolet light, etc. Causes a large decrease in activity.
- proteins such as human serum albumin or purified gelatin, which are commonly used as stabilizers, to suppress these chemical and physical changes. There is something.
- adding a protein as a stabilizing agent involves problems such as the necessity of a very complicated process for removing virus contamination and the like.
- An object of the present invention is to provide a G-CSF preparation which is more stable even for long-term storage and has a low oxidized product formation rate of G-CSF methionine residue.
- the present inventors have found that by adding a specific amino acid in combination as a stabilizer, the G-CSF retention rate is high even after long-term storage, and the G-CSF The present inventors have found that a G-CSF preparation having a low methionine residue oxidized product formation rate can be obtained and completed the present invention.
- the G-CSF residual ratio after the long-term storage test of 25 months is 90% or more, or the G-CSF residual ratio after the long-term storage test of 40 months is 9% or less.
- 0% or more 50 ° C-G-CSF residual rate after 1 month accelerated test is 90% or more
- 60 ° C-G-CSF residual rate after 2 weeks accelerated test Is 90% or more
- the formation rate of methionine residue oxidized form of G-CSF is 1% or less after 50 ° C-1 month accelerated test or 60 ° C-2 weeks accelerated test.
- the present invention further provides one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine, and asparagine.
- the present invention further provides the above-mentioned G-CSF preparation, wherein the hydrophobic amino acid is selected from phenylalanine, tributofan and oral isine.
- the present invention further provides at least one amino acid selected from the group consisting of lysine, histidine, arginine, aspartic acid, and glutamic acid, and at least one amino acid selected from the group consisting of phenylalanine, tryptophan, and leucine; and A G-CSF formulation as described above, comprising zonin.
- the present invention further provides the above-mentioned G-CSF preparation, which comprises phenylalanine, arginine and methionine.
- the present invention further provides the above-mentioned G-CSF preparation substantially free of protein as a stabilizer.
- the present invention further provides the above G-CSF preparation which is a freeze-dried preparation.
- the present invention further provides the aforementioned G-CSF formulation further comprising mannitol.
- the present invention further provides the aforementioned G-CSF formulation, further comprising a surfactant.
- the present invention further provides the above G-CSF preparation, wherein the surfactant is a polyoxyethylene sorbinyl alkyl ester.
- the present invention further provides the above G-CSF formulation, wherein the surfactant is polysorbate 20 and / or 80.
- the present invention further provides the aforementioned G-CSF formulation having a pH of 5 to 7.
- the present invention further provides the above-mentioned G-CSF preparation having a pH of 5.5 to 6.8.
- the present invention further provides the above G-CSF preparation having a pH of 6.5.
- the present invention further provides the above G-CSF preparation, wherein the G-CSF is G-CSF produced from CHO cells.
- the present invention further includes one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glumic acid, threonine, and asparagine, and one or more amino acids selected from hydrophobic amino acids, and has a pH of 5 or more.
- G-CSF residual rate after 3 months long-term storage test Is 90% or more
- G-CSF residual ratio after long-term storage test at 40 ° C for 2 months is 90% or more
- G-CSF residual after accelerated test at 50 ° C for 1 month To provide a stable G-CSF formulation with a G-CSF ratio of 90% or more or a G-CSF residual ratio of 90% or more after an accelerated test at 60 °
- the present invention further includes one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, and dalmic acid, and one or more amino acids selected from the group consisting of phenylalanine, tryptophan, and leucine.
- the G-CSF retention rate after a long-term storage test at 25 ° C for 3 months is 90% or more, or a pH of 5 to 7 after a long-term storage test at 40 ° C for 2 months.
- G—CSF residual rate is 90% or more, or 50 ° C—After 1 month accelerated test
- G—CSF residual rate is 90% or more 60 ° C—After 2 weeks accelerated test
- the present invention further provides any of the above G-CSF preparations having a pH of 6.5.
- the present invention further provides a method for suppressing the production of oxidized methionine residues of a protein, which comprises adding methionine to a composition containing a physiologically active protein having a methionine residue.
- the present invention further provides the above method, wherein the bioactive protein is a cytoactive protein or a bioactive peptide.
- the present invention further provides the above method, wherein the bioactive protein is a colony stimulating factor or PTH.
- the present invention further provides the above method, wherein the bioactive protein is G-CSF, erythropoietin or PTH.
- the present invention further provides the above method, wherein the method does not contain other protein as a stabilizer.
- the present invention further provides the above method, wherein the composition containing a bioactive protein having a methionine residue is lyophilized or in a solution.
- the present invention further provides a methionine residue comprising methionine and one or more other amino acids.
- a stabilized composition containing a bioactive protein having a group.
- the amino acid may further include lysine, histidine, arginine, aspartic acid, glutamic acid, feniralanine, tryptophan, leucine, isoleucine, norin, alanine, proline, glycine, serine, threonine, asparagine, and glutamine.
- the present invention further provides a bioactive protein-containing stabilizing composition having a methionine residue, which does not contain another protein as a stabilizing agent.
- FIG. 1 shows chromatograms of Samples 34 and 36, which were subjected to an acceleration test at 60 ° C. for 2 weeks and then performed by the method described in Method 2 described below.
- Figure 2 shows the chromatograms of Samples 34 to 36 immediately after preparation and after a 1 month accelerated test at 50 ° C, performed by Method 2 described below.
- FIG. 3 is an HPLC chromatogram showing the inhibitory effect of addition of methionine on the oxidation of methionine residues when the paraside hormone solution preparation was subjected to the method shown in Example 6 (storage at 50 ° C. for 3 days).
- the largest peak in the center is the unchanged PTH
- the Met-8 peak and the Met-18 peak are PTH in which the eighth methionine residue is oxidized and the 18th methionine residue, respectively.
- the radical is oxidized PTH.
- G-CSF used in the preparation of the present invention can be any human G-CSF that has been purified to high purity. Specifically, it has substantially the same biological activity as mammals, especially human G-CSF, and includes those derived from nature and those obtained by genetic recombination. G-CSF obtained by the genetic recombination method has the same amino acid sequence as natural G-CSF, or has one or more amino acid sequences deleted, substituted, or added, and has the above-mentioned biological activity.
- the G-CSF in the present invention may be produced by any method, and is obtained by culturing a cell line of human tumor cells, extracting and purifying it by various methods, Bacteria such as Escherichia coli, yeast, and hamster ovary (CHO) cells, C127 cells, and other animal-derived cultured cells produced by genetic engineering techniques, and extracted and separated and purified by various methods. Is used. Preferably, it is produced by a genetic recombination method using Escherichia coli, a list of bacteria or CHO cells. Most preferably, it is produced by a CHO cell using a genetic recombination method.
- the G—CSF preparation of the present invention preferably contains substantially no protein such as human serum albumin or purified gelatin as a stabilizer.
- the G-CSF preparation of the present invention has a G-CSF residual ratio of 90% or more, preferably 95% or more after a long-term storage test at 25 ° C for 3 months, or a temperature of 40 ° C for a 2-month long-term storage test.
- G-CSF residual rate at 90% or more, preferably 95% or more at 50 ° C-G-CSF residual rate after an accelerated test for one month is 90% or more, preferably 95% or more
- the G-CSF residual rate after the accelerated test at 60 ° C for 2 weeks is 90% or more, preferably 95% or more, and at 50 ° C after the accelerated test for 1 month or at 60 ° C.
- G-CSF methionine residue after accelerated test for 2 weeks Oxidant generation rate is 1% or less, preferably below the detection limit, and it is extremely stable compared to conventionally known G-CSF preparations .
- G-CSF preparation of the present invention is one or more amino acids selected from the group consisting of lysine, histidine, arginine, asparaginic acid, glutamic acid, threonine, and asparagine, preferably lysine, histidine, arginine, asparaginic acid, and glutamic acid.
- G comprising at least one amino acid selected from the group consisting of: and one or more amino acids selected from hydrophobic amino acids, preferably one or more amino acids selected from the group consisting of phenylalanine, tryptophan and leucine; and methionine.
- CSF formulation is one or more amino acids selected from the group consisting of lysine, histidine, arginine, asparaginic acid, glutamic acid.
- G comprising at least one amino acid selected from the group consisting of: and one or more amino acids selected from hydrophobic amino acids, preferably one or more amino acids selected from the group consisting of phenylalanine, trypto
- one example of the G-CSF preparation of the present invention includes one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine, and asparagine, preferably lysine, histidine, arginine, and aspartic acid.
- G-CSF residual rate after 60 ° C-2 weeks accelerated test is 90% or more, and 50 ° C-1 month accelerated test or 60 ° C-2 weeks It is a stable G-CSF preparation that has an oxidized form of methionine residue of G-CSF of 1% or less after accelerated test.
- the amino acids used in the present invention include free amino acids and salts thereof such as sodium salts, potassium salts, and hydrochlorides.
- the formulation of the present invention contains D-, L- and D-L of these amino acids, more preferably L- and its salts.
- the preferred range of the amount of the amino acid to be added to the preparation of the present invention can be determined by the test method described later, depending on the type of the amino acid used. Generally, the final dose is 0.001 to 5 Omg / m1.
- the amount is preferably from 0.001 to 5 mgZmI, more preferably from 0.01 to 4 mgZmI.
- polyethylene glycol in the preparation of the present invention, polyethylene glycol; saccharides such as dextran, mannitol, sorbitol, inositol, glucose, fruc 1 ⁇ , lactose, xylose, mannose, maltose, sucrose, and raffinose Can be used. Mannitol is particularly preferred.
- the amount of mannitol to be added is 1 to 10 OmgZm1, more preferably 5 to 6 Omgm1 in the preparation.
- the formulation of the present invention may further include a surfactant.
- the surfactant include nonionic surfactants such as sorbitan monocaprylate, sorbitan monolaurate, and sorbitan fatty acid esters such as sorbitan monopalmitate; glycerin monocaprylate, glycerin monomitrate, and the like.
- Glycerin fatty acid esters such as glycerin monostearate; decaglyceryl monostearate, decaglycer Polyglycerin fatty acid esters such as rildistearate and decaglyceryl monolinoleate; polyoxyethylene sorbitan monolaurate, polyoxyethylene
- Polyoxyethylene sorbitan fatty acid esters such as trioleate and polyoxyethylene sorbitan tristearate; polyoxyethylene sorbite fatty acid esters such as polyoxyethylene sorbite tetrastearate and polyoxyethylene sorbite tetraoleate; polyoxyethylene glyceryl Polyoxyethylene glycerin fatty acid esters such as monostearate; polyethylene glycol fatty acid esters such as polyethylene glycol distearate; polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether; polyoxyethylene polypropylene propylene glycol ether; Tylene polyoxypropylene propyl ether, polyoxyethylene polyoxypropylene cetyl ether Polyoxyethylene alkylphenyl ethers such as polyoxyethylenyl nonylphenyl ether; polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil (poly) Hydrogenated castor oil, such as hydrogenated castor oil); polyoxyethylene bees
- Preferred surfactants are polyoxyethylene sorbitan fatty acid esters, particularly preferred are polysorbates 20, 21, 40, 60, 65, 80, 81, 85, most preferred are polysorbates. 20 and 80.
- the amount of the surfactant to be added to the G-CSF-containing preparation of the present invention is generally 0.0001 to 10 parts by weight based on 1 part by weight of G-CSF, and preferably 1 part by weight of G-CSF.
- the amount is 0.01 to 5 parts by weight, most preferably 0.2 to 2 parts by weight based on 1 part by weight of G-CSF.
- the pH of the G-CSF preparation of the present invention is preferably from 5 to 7, more preferably from 5.5 to 6.8, even more preferably from 6 to 6.7, most preferably pH is 6.5.
- the G-CSF preparation of the present invention may further contain a diluent, a dissolution aid, an excipient, a pH adjuster, a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like, if desired.
- sulfur-containing reducing agents include N-acetyl cysteine, N-acetyl homocystin, thioctic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, and sodium thiosulfate.
- antioxidants include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, heart tocopherol, tocopherol acetate, L-ascorbic acid and its salts, L-ascorbic acid palmitate, and L-ascorbic acid stearate.
- chelating agents such as sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or disodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate and sodium metaphosphate.
- inorganic salts such as sodium chloride, potassium chloride, sodium chloride, sodium phosphate, potassium phosphate, and sodium hydrogen carbonate; and organic salts such as sodium citrate, potassium citrate, and sodium acetate are usually added. May be included.
- the G-CSF preparation of the present invention includes a solution preparation, a freeze-dried preparation, a spray-dried preparation and the like. Most preferably, it is a freeze-dried preparation.
- a phosphate buffer preferably, sodium monohydrogen phosphate-sodium dihydrogen phosphate
- a citrate buffer preferably, a sodium citrate buffer
- a solution preparation can be prepared by dissolving in an aqueous buffer known in the field of the solution preparation, or by freeze-drying or spray-drying the thus prepared solution preparation by a conventional method.
- the stabilized G-CSF-containing preparation of the present invention is usually administered by parenteral administration route, for example, injection (subcutaneous injection, intravenous injection, intramuscular injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc. Oral administration is also possible.
- parenteral administration route for example, injection (subcutaneous injection, intravenous injection, intramuscular injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc.
- parenteral administration route for example, injection (subcutaneous injection, intravenous injection, intramuscular injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc.
- parenteral administration route for example, injection (subcutaneous injection, intravenous injection, intramuscular injection, etc.), transdermal, transmucosal, nasal, pulmonary, etc.
- Oral administration is also possible.
- the G-CSF preparation of the present invention is usually contained in a sealed or sterilized plastic or glass container, and is dissolved in pure water (sterile water for injection) before use.
- the amount of G—CSF contained in the preparation of the present invention can be determined according to the type of the disease to be treated, the severity of the disease, the age of the patient, and the like. In general, the final administration concentration is 1 to 1,000 g. / m 1, preferably 10 to 800 g / m 1, more preferably 50 to 500 gZm 1.
- the formulation of the present invention provides protection based on the immune response such as resistance and activity of patients when administered simultaneously with the administration of antibiotics, antibacterial agents, anticancer agents, etc. in the chemotherapy of infectious diseases and cancer. It has been shown to improve function and is extremely useful clinically. Therefore, the preparation of the present invention can be administered in combination with these drugs.
- the G-CSF preparation of the present invention may be subjected to a long-term storage test at 25 ° C for 3 months or a long-term storage test at 40 ° C for 2 months, or at 50 ° C for 1 month. It shows extremely good G-CSF residual rate even after the accelerated test at 60 ° C for 2 weeks.
- the G-CSF preparation of the present invention has a G-CSF residual ratio of 90% or more, preferably 95% or more after a storage test at 25 ° C for 3 months.
- G-CSF residual rate is 90% or higher, preferably 95% or higher, or 50 ° C-G-CSF residual rate after one month accelerated test is 90% or higher, preferably 95% or higher Force, 60 ° C—after 2 weeks accelerated test G-CSF at 90% or more, preferably 95% or more at 50 ° C and after one month accelerated test or 60 ° C and two weeks accelerated test Is less than 1%, preferably less than the detection limit.
- amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine, and asparagine selected from hydrophobic amino acids
- the addition of amino acid can increase the G_CSF residual rate especially after long-term storage at room temperature, and the addition of methionine reduces the rate of formation of oxidized methionine residue of G-CSF. Below the detection limit was observed.
- the present inventors oxidize the added methionine in place of the methionine residue of G_CSF, thereby obtaining an oxidized form of the methionine residue of G-CSF. It was speculated that the production rate would be low.
- methionine it is particularly preferable to add methionine to a composition of a bioactive protein having a methionine residue, which is more susceptible to the formation of an oxidized form of a methionine residue and has a trace amount of bioactivity.
- methionine residue of the physiologically active protein.
- the bioactive protein composition does not contain another protein as a stabilizer, when the protein composition is freeze-dried, or when the protein composition is in a solution state, protein It is considered that the addition of methionine is effective because an oxidized form of methionine residue is easily generated.
- composition of the present invention by adding one or more other amino acids to the composition of the present invention, the formation of oxidized methionine residues was suppressed, and the degradation, aggregation, etc. of bioactive proteins were suppressed, and the composition was stabilized.
- a bioactive protein-containing composition having a methionine residue can be produced.
- the amino acids to be added at this time include lysine, histidine, arginine, aspartic acid, glutamic acid, fenylalanine, tributofan, leucine, isoleucine, norin, alanine, proline, glycine, serine, threonine, asparagine, glutamine, Tyrosine and the like are exemplified, and histidine, arginine, and phenylalanine are preferred.
- the bioactive protein of the present invention include:
- interleukin interleukin (IL-11 to IL-13 etc.), colony stimulating factor (granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM—CSF), erythropoietin (EPO), etc., interferon (IFN— ⁇ , ⁇ , R, etc.), tumor necrosis factor (TNF— ⁇ , TNF—
- G-CSF colony stimulating factor
- M-CSF macrophage colony stimulating factor
- GM—CSF granulocyte macrophage colony stimulating factor
- EPO erythropoietin
- interferon IFN— ⁇ , ⁇ , R
- Physiologically active peptides insulin, glucagon, parathyroid hormone (PTH), gastrin, selectin, cholecystokinin,neededric inhibitory polypeptide, polypeptide, substance P, motilin, spleen polypeptide, neurotensin, enteroglucagon , Gastrin-releasing peptide, somatosustin-28, dynorphin, galanin, baronin, pancreostatin, zeopsin, etc.
- biological enzymes enzymes having methionine residues in the active center (eg, malate dehydrogenase, etc.), etc.
- the bioactive protein of the present invention is preferably a cytodynamic protein or a bioactive peptide, more preferably a G-CSF, a colloid stimulator such as erythropoietin or PTH, and further preferably a G-CSF , Erythrobotin or PTH.
- the freeze-dried preparation containing G-CSF aseptically prepared in this manner is placed in a thermostat at 60 ° C for 2 weeks and 1 month; in a thermostat of 50 months, 1 month, 2 months and 3 months; 2 months, 4 months, 6 months; and 3 months, 6 months in a 25 ° C constant temperature bath.
- Accelerated product and unaccelerated product were accurately dissolved in 1 mL of pure water, and used as test samples by the following method.
- the G—CSF content (residual rate) in the vial was measured according to the following method 1.
- the production rate of oxidized G—CSF methionine residue in the vial was measured based on Method 2 below.
- the G-CSF content of the sample was determined by reversed-phase high-performance liquid chromatography using a C4 reversed-phase column (4.6 mm x 250 mm, 300 ⁇ ) using pure water, acetonitrile, and trifluoroacetic acid as the mobile phase. It was measured. An equivalent of 5 fig was injected as G-CSF, G-CSF was eluted with an acetonitrile gradient, and detected spectrophotometrically at a wavelength of 215 nm.
- the G-CSF unchanged product was obtained by reversed-phase high-performance liquid chromatography using pure water, acetonitrile, and trifluoroacetic acid as the mobile phase using a C4 reversed-phase column (4.6 mm x 250 mm, 300 ⁇ ). And oxidized form of G—CSF Met residue was measured. G-CSF eluted with acetonitrile gradient And detected spectrophotometrically at a wavelength of 215 nm.
- Samples 11 to 20 prepared by adding various amino acids shown in Table 1 (Fenilalanine as amino acid 1, lysine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine, asparagine as amino acid 2) And glutamine), and samples 21 to 33 (arginine as amino acid 1, alanine, valine, leucine, isoleucine, methionine, amino acid 2, tryptophan, phenylalanine, proline, glycine, serine, threonine, asparagine and Glutamine was added), and the G-CSF residual rate after the accelerated test at 60 ° C for 2 weeks and for 50 to 1 month was calculated by the formula described in Method 1. Tables 6 and 7 show the obtained results. [Table 6]
- Example 5 Effect of addition of amino acid on the formation rate of oxidized G-CSF Met residue
- Samples 34 to 36 prepared by adding each amount of methionine described in Table 2 (the amounts of phenylalanine and arginine are constant) Methionine was added at Omg, 0.1 mg, and lmg, respectively), and an accelerated test was performed at 60 for 2 weeks.
- Fig. 2 shows an example of the chromatogram performed by the above method 2 after the one-month accelerated test.
- Table 9 shows the results of calculating the oxidized G-CSF Met residue generation rate by the formula described in Method 2.
- Parathyroid hormone having 1 to 84 residues (hereinafter abbreviated as PTH) (produced by the method described in W9104415) containing 200 gZmL, and the amount of each raw material added per vial was Prepare the preparations of Samples 37 to 39 as shown in Table 10 below, perform aseptic filtration, and then aseptically fill each vial accurately with lmL, stopper completely, and complete PTH. A solution formulation was prepared.
- the PTH-containing solution preparation aseptically prepared in this manner was allowed to stand in a thermostat at 50 ° C. for 3 days.
- the sample was a reversed-phase high-performance liquid chromatography method using a C18 reverse-phase column (4.6 mm x 250 mm, 300 Angstrom mouth) using pure water, acetonitrile, and trifluoroacetic acid as the mobile phase.
- the PTH content was determined according to An amount equivalent to 10 ULg was injected as PTH, and PTH was eluted with an acetonitrile gradient, and detected spectrophotometrically at a wavelength of 215 nm.
- the G-CSF preparation of the present invention has a very high residual ratio of G-CSF even after long-term storage, and is a stable preparation capable of almost completely suppressing the generation rate of oxidized methionine residue of G-CSF. It is.
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00905397A EP1197221B1 (en) | 1999-03-01 | 2000-02-29 | G-csf preparations stabilized over long time |
AU26954/00A AU772604B2 (en) | 1999-03-01 | 2000-02-29 | Long-term stabilized formulations |
CA2381229A CA2381229C (en) | 1999-03-01 | 2000-02-29 | Stabilized g-csf preparations |
US09/914,641 US6908610B1 (en) | 1999-03-01 | 2000-02-29 | Long-term stabilized formulations |
DE60028037T DE60028037T2 (de) | 1999-03-01 | 2000-02-29 | LANGFRISTIG STABILISIERTE G-CSF PRäPARATE |
JP2000602295A JP4607336B2 (ja) | 1999-03-01 | 2000-02-29 | 長期安定化製剤 |
HK02107149.3A HK1045652A1 (zh) | 1999-03-01 | 2002-09-27 | 長期穩定的製劑 |
HK02107478.4A HK1046239B (zh) | 1999-03-01 | 2002-10-16 | 長期穩定的g-csf製劑 |
CY20061101080T CY1105528T1 (el) | 1999-03-01 | 2006-08-02 | Παρασκευaσματα σταθεροποιημeνα για μακρo διaστημα |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/52314 | 1999-03-01 | ||
JP11052314A JP2000247903A (ja) | 1999-03-01 | 1999-03-01 | 長期安定化製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000051629A1 true WO2000051629A1 (fr) | 2000-09-08 |
Family
ID=12911333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/001160 WO2000051629A1 (fr) | 1999-03-01 | 2000-02-29 | Preparations stabilisees a longue conservation |
Country Status (16)
Country | Link |
---|---|
US (1) | US6908610B1 (ja) |
EP (2) | EP1700605B1 (ja) |
JP (2) | JP2000247903A (ja) |
KR (2) | KR100731559B1 (ja) |
CN (3) | CN1342087A (ja) |
AT (1) | ATE326233T1 (ja) |
AU (1) | AU772604B2 (ja) |
CA (1) | CA2381229C (ja) |
CY (1) | CY1105528T1 (ja) |
DE (1) | DE60028037T2 (ja) |
DK (1) | DK1197221T3 (ja) |
ES (1) | ES2263450T3 (ja) |
HK (3) | HK1045652A1 (ja) |
PT (1) | PT1197221E (ja) |
TW (1) | TWI232749B (ja) |
WO (1) | WO2000051629A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048117A1 (fr) * | 1999-12-24 | 2001-07-05 | Otsuka Pharmaceutical Co., Ltd. | Compositions seches contenant un acide amine hydrophobe |
WO2002017957A1 (fr) * | 2000-09-01 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations de solutions stabilisees sur une longue periode de temps |
WO2004019966A1 (ja) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
JP2005511520A (ja) * | 2001-10-05 | 2005-04-28 | ビスカム・アーゲー | 組換え炭水化物結合ポリペプチドの安定型凍結乾燥生薬製剤 |
JP2005527470A (ja) * | 2001-08-30 | 2005-09-15 | キリン−アムジエン・インコーポレーテツド | Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン |
JP2006515321A (ja) * | 2002-08-16 | 2006-05-25 | ブラッコ インターナショナル ビー.ヴイ. | シンカリド製剤 |
US7202208B2 (en) * | 2000-05-15 | 2007-04-10 | Hoffman-La Roche Inc. | Erythropoietin composition |
JP2007536215A (ja) * | 2004-03-10 | 2007-12-13 | ビオシューティカルズ アールツナイミテル アクチェンゲゼルシャフト | 液体エリスロポエチン製剤 |
EP1260230A4 (en) * | 2000-02-29 | 2008-08-06 | Chugai Pharmaceutical Co Ltd | LONG-TERM STABILIZED PREPARATIONS |
US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
WO2015076285A1 (ja) * | 2013-11-21 | 2015-05-28 | 協和メデックス株式会社 | 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法 |
JP2019073543A (ja) * | 2017-09-22 | 2019-05-16 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
IL162239A0 (en) | 2001-12-21 | 2005-11-20 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
JP4259324B2 (ja) * | 2002-02-28 | 2009-04-30 | ニプロ株式会社 | 安定化されたアルブミン製剤 |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
KR101212025B1 (ko) * | 2002-06-21 | 2013-01-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물 |
EP1598074B1 (en) * | 2003-02-28 | 2019-01-02 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
AU2004222625A1 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
ES2349779T5 (es) * | 2003-04-04 | 2013-11-26 | Genentech, Inc. | Formulaciones de anticuerpos y de proteínas a concentración elevada |
ATE454900T1 (de) * | 2003-05-23 | 2010-01-15 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
DE602004023848D1 (de) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | Von factor vii polypeptiden |
FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
CN102872451A (zh) * | 2003-08-14 | 2013-01-16 | 诺和诺德医疗保健公司 | 因子vii多肽类的含水液体药物组合物 |
JP2007534633A (ja) * | 2003-11-10 | 2007-11-29 | アライバ−プロメティック インコーポレイティド | ヒト・アルファ1−抗トリプシン製剤 |
US20080312136A1 (en) * | 2003-11-14 | 2008-12-18 | Manzer Durrani | Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions |
KR20130026498A (ko) * | 2003-12-19 | 2013-03-13 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 안정화된 조성물 |
JP2005310840A (ja) | 2004-04-16 | 2005-11-04 | Toshiba Corp | 磁気ランダムアクセスメモリ |
US20060293243A1 (en) * | 2005-06-17 | 2006-12-28 | Navneet Puri | Stable, buffered, pharmaceutical compositions including motilin-like peptides |
US7534753B2 (en) * | 2006-01-12 | 2009-05-19 | Air Products And Chemicals, Inc. | pH buffered aqueous cleaning composition and method for removing photoresist residue |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
US8546329B2 (en) * | 2006-03-22 | 2013-10-01 | Chugai Seiyaku Kabushiki Kaisha | Erythropoietin solution preparation |
CN101657187B (zh) * | 2007-04-05 | 2012-07-18 | 桑多斯股份公司 | 稳定的水性g-csf制剂 |
US20080286471A1 (en) * | 2007-05-18 | 2008-11-20 | Doubleday Marc D | Protective gel for an electrical connection |
MX2009013886A (es) * | 2007-06-25 | 2010-01-27 | Amgen Inc | Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos. |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
EP2684570A1 (en) * | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
RU2011140498A (ru) | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | Препарат антител |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
TWI468171B (zh) | 2009-11-13 | 2015-01-11 | Sanofi Aventis Deutschland | 含glp-1激動劑及甲硫胺酸之醫藥組成物 |
UA112288C2 (uk) * | 2010-01-15 | 2016-08-25 | Кірін-Емджен, Інк. | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими |
TWI505838B (zh) * | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
CN110835373A (zh) | 2010-03-01 | 2020-02-25 | 拜耳医药保健有限公司 | 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体 |
EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
CN102028661B (zh) * | 2010-12-31 | 2012-05-23 | 山东新时代药业有限公司 | 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
WO2013142336A1 (en) * | 2012-03-21 | 2013-09-26 | Miller Leonard B | Combination therapy to improve joint, tendon, and ligament healing |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
ES2694328T3 (es) | 2013-03-12 | 2018-12-19 | Sumitomo Dainippon Pharma Co., Ltd. | Composición acuosa líquida |
RU2707092C2 (ru) * | 2013-03-13 | 2019-11-22 | Дженентек, Инк. | Составы со сниженным окислением |
CA3135558A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Prevention of protein oxidation in a composition |
AR095398A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida |
AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
CN104524553B (zh) * | 2014-12-12 | 2015-07-29 | 薛传校 | 一种长效促排卵注射液 |
CR20170314A (es) | 2014-12-12 | 2017-10-20 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
CN109627300B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin溶液稳定剂开发及应用 |
WO2021195877A1 (en) * | 2020-03-30 | 2021-10-07 | Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. | Formulations of human parathyroid hormone (pth) and methods for producing same |
WO2023066988A1 (en) | 2021-10-19 | 2023-04-27 | Sandoz Ag | Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents |
CN115624187B (zh) * | 2022-12-08 | 2023-04-04 | 北京第一生物科技开发有限公司 | 牛脾肽粉在改善睡眠中的用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63146829A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
US4915945A (en) * | 1982-07-30 | 1990-04-10 | Behringwerke Aktiengesellschaft | Process for the preparation of the C1 inactivator |
JPH03287540A (ja) * | 1990-04-03 | 1991-12-18 | Teikoku Hormone Mfg Co Ltd | カルシトニン注射液 |
WO1992015614A1 (en) * | 1991-03-01 | 1992-09-17 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
JPH05331071A (ja) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
WO1994013143A1 (en) * | 1992-12-08 | 1994-06-23 | Applied Microbiology, Inc. | Stabilized lanthionine bacteriocin compositions |
WO1994014465A1 (de) * | 1992-12-18 | 1994-07-07 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische zubereitungen von g-csf |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
EP0853945A1 (en) * | 1997-01-15 | 1998-07-22 | Akzo Nobel N.V. | Liquid gonadotropin containing formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
GB9120304D0 (en) * | 1991-09-24 | 1991-11-06 | Erba Carlo Spa | Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
CZ305123B6 (cs) * | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
-
1999
- 1999-03-01 JP JP11052314A patent/JP2000247903A/ja active Pending
-
2000
- 2000-02-29 CN CN00804421A patent/CN1342087A/zh active Pending
- 2000-02-29 CA CA2381229A patent/CA2381229C/en not_active Expired - Lifetime
- 2000-02-29 WO PCT/JP2000/001160 patent/WO2000051629A1/ja active IP Right Grant
- 2000-02-29 CN CNA2009101329481A patent/CN101537173A/zh active Pending
- 2000-02-29 PT PT00905397T patent/PT1197221E/pt unknown
- 2000-02-29 AT AT00905397T patent/ATE326233T1/de active
- 2000-02-29 EP EP06010059.1A patent/EP1700605B1/en not_active Expired - Lifetime
- 2000-02-29 DE DE60028037T patent/DE60028037T2/de not_active Expired - Lifetime
- 2000-02-29 EP EP00905397A patent/EP1197221B1/en not_active Expired - Lifetime
- 2000-02-29 KR KR1020057017282A patent/KR100731559B1/ko active IP Right Grant
- 2000-02-29 AU AU26954/00A patent/AU772604B2/en not_active Expired
- 2000-02-29 DK DK00905397T patent/DK1197221T3/da active
- 2000-02-29 US US09/914,641 patent/US6908610B1/en not_active Expired - Lifetime
- 2000-02-29 ES ES00905397T patent/ES2263450T3/es not_active Expired - Lifetime
- 2000-02-29 CN CN2006100923765A patent/CN1879875B/zh not_active Expired - Lifetime
- 2000-02-29 KR KR1020017011145A patent/KR100656125B1/ko active IP Right Grant
- 2000-02-29 JP JP2000602295A patent/JP4607336B2/ja not_active Expired - Lifetime
- 2000-03-01 TW TW089103623A patent/TWI232749B/zh not_active IP Right Cessation
-
2002
- 2002-09-27 HK HK02107149.3A patent/HK1045652A1/zh unknown
- 2002-10-16 HK HK02107478.4A patent/HK1046239B/zh not_active IP Right Cessation
-
2006
- 2006-08-02 CY CY20061101080T patent/CY1105528T1/el unknown
-
2007
- 2007-06-15 HK HK07106471.8A patent/HK1098963A1/xx not_active IP Right Cessation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4915945A (en) * | 1982-07-30 | 1990-04-10 | Behringwerke Aktiengesellschaft | Process for the preparation of the C1 inactivator |
JPS63146829A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH03287540A (ja) * | 1990-04-03 | 1991-12-18 | Teikoku Hormone Mfg Co Ltd | カルシトニン注射液 |
WO1992015614A1 (en) * | 1991-03-01 | 1992-09-17 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
JPH05331071A (ja) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
WO1994013143A1 (en) * | 1992-12-08 | 1994-06-23 | Applied Microbiology, Inc. | Stabilized lanthionine bacteriocin compositions |
WO1994014465A1 (de) * | 1992-12-18 | 1994-07-07 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische zubereitungen von g-csf |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
EP0853945A1 (en) * | 1997-01-15 | 1998-07-22 | Akzo Nobel N.V. | Liquid gonadotropin containing formulations |
Non-Patent Citations (1)
Title |
---|
RIISOM T. ET AL.: "Effect of amino acids on the autoxidation of safflower oil in emulsions", J. AM. OIL CHEM. SOC., vol. 57, no. 10, 1980, pages 354 - 359, XP002926016 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048117A1 (fr) * | 1999-12-24 | 2001-07-05 | Otsuka Pharmaceutical Co., Ltd. | Compositions seches contenant un acide amine hydrophobe |
EP1260230A4 (en) * | 2000-02-29 | 2008-08-06 | Chugai Pharmaceutical Co Ltd | LONG-TERM STABILIZED PREPARATIONS |
US7202208B2 (en) * | 2000-05-15 | 2007-04-10 | Hoffman-La Roche Inc. | Erythropoietin composition |
WO2002017957A1 (fr) * | 2000-09-01 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations de solutions stabilisees sur une longue periode de temps |
US7998929B2 (en) | 2000-09-01 | 2011-08-16 | Chugai Seikyaku Kabushiki Kaisha | Solution preparations stabilized over long time |
JP2005527470A (ja) * | 2001-08-30 | 2005-09-15 | キリン−アムジエン・インコーポレーテツド | Hsa非含有組成物中のnesp/epoの安定化剤としてのl−メチオニン |
JP2005511520A (ja) * | 2001-10-05 | 2005-04-28 | ビスカム・アーゲー | 組換え炭水化物結合ポリペプチドの安定型凍結乾燥生薬製剤 |
JP4751993B2 (ja) * | 2002-08-16 | 2011-08-17 | ブラッコ スイス エス.エー. | シンカリド製剤 |
JP2006515321A (ja) * | 2002-08-16 | 2006-05-25 | ブラッコ インターナショナル ビー.ヴイ. | シンカリド製剤 |
JP4489591B2 (ja) * | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
JPWO2004019966A1 (ja) * | 2002-08-27 | 2005-12-15 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
WO2004019966A1 (ja) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
JP2007536215A (ja) * | 2004-03-10 | 2007-12-13 | ビオシューティカルズ アールツナイミテル アクチェンゲゼルシャフト | 液体エリスロポエチン製剤 |
US7767644B2 (en) * | 2004-03-10 | 2010-08-03 | Bioceuticals Arzneimittel Ag | Erythropoietin liquid formulation |
JP4887281B2 (ja) * | 2004-03-10 | 2012-02-29 | ビオシューティカルズ アールツナイミテル アクチェンゲゼルシャフト | 液体エリスロポエチン製剤 |
US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
US9220780B2 (en) | 2007-07-10 | 2015-12-29 | Medy-Tox Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
WO2015076285A1 (ja) * | 2013-11-21 | 2015-05-28 | 協和メデックス株式会社 | 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法 |
JPWO2015076285A1 (ja) * | 2013-11-21 | 2017-03-16 | 協和メデックス株式会社 | 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法 |
JP2019073543A (ja) * | 2017-09-22 | 2019-05-16 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
JP2019089865A (ja) * | 2017-09-22 | 2019-06-13 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
ATE326233T1 (de) | 2006-06-15 |
DE60028037T2 (de) | 2006-12-21 |
TWI232749B (en) | 2005-05-21 |
EP1197221B1 (en) | 2006-05-17 |
CA2381229C (en) | 2010-10-26 |
AU2695400A (en) | 2000-09-21 |
HK1098963A1 (en) | 2007-08-03 |
KR20050099637A (ko) | 2005-10-14 |
PT1197221E (pt) | 2006-08-31 |
EP1700605A3 (en) | 2007-06-13 |
KR20010102469A (ko) | 2001-11-15 |
CN101537173A (zh) | 2009-09-23 |
KR100731559B1 (ko) | 2007-06-22 |
CN1879875A (zh) | 2006-12-20 |
CA2381229A1 (en) | 2000-09-08 |
AU772604B2 (en) | 2004-05-06 |
HK1046239B (zh) | 2006-08-18 |
US6908610B1 (en) | 2005-06-21 |
HK1045652A1 (zh) | 2002-12-06 |
EP1700605A2 (en) | 2006-09-13 |
ES2263450T3 (es) | 2006-12-16 |
CY1105528T1 (el) | 2010-07-28 |
EP1197221A4 (en) | 2003-01-29 |
CN1879875B (zh) | 2010-08-25 |
KR100656125B1 (ko) | 2006-12-12 |
DE60028037D1 (de) | 2006-06-22 |
CN1342087A (zh) | 2002-03-27 |
HK1046239A1 (en) | 2003-01-03 |
JP4607336B2 (ja) | 2011-01-05 |
EP1700605B1 (en) | 2014-04-30 |
DK1197221T3 (da) | 2006-11-13 |
JP2000247903A (ja) | 2000-09-12 |
EP1197221A1 (en) | 2002-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000051629A1 (fr) | Preparations stabilisees a longue conservation | |
JP2007204498A (ja) | 長期安定化製剤 | |
JP4683810B2 (ja) | 長期安定化製剤 | |
JP4589018B2 (ja) | エリスロポエチン溶液製剤 | |
US7998929B2 (en) | Solution preparations stabilized over long time | |
JP3895109B2 (ja) | 蛋白非添加製剤 | |
JPS63146826A (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP4454571B2 (ja) | 蛋白非添加製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00804421.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 26954/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2000 602295 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914641 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011145 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000905397 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017011145 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2381229 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2000905397 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 26954/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017011145 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000905397 Country of ref document: EP |